At its 2026 Annual Meeting of Stockholders held on July 9, 2026, Cingulate Inc. stockholders approved Amendment No. 3 to the 2021 Omnibus Equity Incentive Plan, increasing authorized shares by 625,000 to a total of 2,221,126. The Board of Directors reduced its size to five members and appointed CEO Shane Schaffer as chairman, with Jeff Hargroves serving as lead independent director. Jeff Hargroves was also elected as a Class II director. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Cingulate Inc. is a technology company focused on diagnostic solutions.

Cingulate Inc. announced that its wholly owned subsidiary, Cingulate Therapeutics LLC, amended the employment agreement for Matthew N. Brams, Executive Vice President and Chief Medical Officer,<pad> extending his full-time employment trial period from June 30, 2026, to September 30, 2026. Additionally, the company<pad> announced its selection for membership in the Russell 3000E Index. Cingulate Inc. is a biotechnology company.

Cingulate Inc. announced on June 16, 2026, that the United States Patent and Trademark Office issued U.S. Patent No. 12,653,791, covering key aspects of CTx-1301's formulation and method of use through December 2042. Cingulate Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and neuropsychiatric disorders.